Research Article

Evaluation of the Feasibility of Screening Tau Radiotracers Using an Amyloid Biomathematical Screening Methodology

Table 2

Comparison of predicted and clinically observed K1, k2, and BPND values of four clinically applied tau radiotracers.

RadiotracersLiteraturePredicted values% diff
ParametersRegionClinically observed valuesReferences

[18F]flortaucipirK1Cerebellum excluding vermis0.26[36]0.256−1.54
k20.170.19917.1
[18F]THK5351 (S-enantiomer of [18F]THK5151)k2Targetβ0.115[38]0.14021.7
[18F]THK5317 (S-enantiomer of [18F]THK5117)K1Targetδ0.33[35]0.202−38.8
k20.090.087−3.33
BPND (AD)Putamen0.60[39]0.125−79.2
[11C]PBB3BPND (AD)High-binding cortical regions0.37[10]0.42715.4
[18F]MK6240K1Posterior cingulate cortex0.246[16]0.2522.50
k20.0990.13839.2
BPND§5.118.1359.2

βTarget ROIs: anterior cingulate, brainstem, caudate nucleus, eroded white matter, entorhinal cortex, frontal cortex, fusiform gyrus, hippocampus, inferior temporal cortex, lingual gyrus, middle temporal gyrus, occipital cortex, pallidum, parahippocampal gyrus, parietal cortex, posterior cingulate, precuneus, putamen, thalamus. δTarget ROIs: thalamus, putamen, hippocampus, amygdala, parietal cortex, frontal cortex, sensory motor cortex, occipital cortex, midbrain, entorhinal cortex, and temporal cortex. BPND = DVR-1, where DVR was determined using reference Logan, averaged from 4 prodromal AD. BPND determined using MRTM0. §BPND determined using k3/k4 using 2T4CM in 7 symptomatic individuals classified as MCI and AD. k2 optimized from fitting all target ROIs using SRTM with cerebellum as the reference region.